表纸
市场调查报告书
商品编码
232823

B型肝炎:开发中产品分析

Hepatitis B (Infectious Disease) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 654 Pages | 订单完成后即时交付

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

  • 全貌
  • 简介
  • 目录
简介

B型肝炎是危险到会威胁生命的肝脏感染症。B型肝炎病毒是造成黄胆、尿液暗沈、严重倦怠、恶心、呕吐、伴随腹痛的急性疾病的原因。B型肝炎致病风险因子有年龄、严重的肾脏病、血友病、重覆使用的注射针头、由感染B型肝炎的母亲所生下的婴儿等。 可用抗病毒药物等治疗。

本报告提供B型肝炎治疗药的开发情形相关调查,提供开发中产品的概要,临床实验的各阶段产品概要,主要企业简介,药物简介,开发中产品的最新趋势等资讯。

简介

B型肝炎概要

治疗药的开发

治疗药的评估

开发治疗药的企业

药物简介

暂停中的计划

开发中止的产品

产品开发的里程碑

附录

图表

目录
Product Code: GMDHC13105IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2021, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 5, 46, 36, 4, 102, 43 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 8 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Hepatitis B - Overview
  • Hepatitis B - Therapeutics Development
  • Hepatitis B - Therapeutics Assessment
  • Hepatitis B - Companies Involved in Therapeutics Development
  • Hepatitis B - Drug Profiles
  • Hepatitis B - Dormant Projects
  • Hepatitis B - Discontinued Products
  • Hepatitis B - Product Development Milestones
  • Appendix

List of Tables

List of Tables

  • Number of Products under Development for Hepatitis B, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Hepatitis B - Pipeline by Abhelix LLC, 2021
  • Hepatitis B - Pipeline by Ai-biopharma SAS, 2021
  • Hepatitis B - Pipeline by AiCuris AG, 2021
  • Hepatitis B - Pipeline by Akshaya Bio Inc, 2021
  • Hepatitis B - Pipeline by Aligos Therapeutics Inc, 2021
  • Hepatitis B - Pipeline by AlloVir Inc, 2021
  • Hepatitis B - Pipeline by AlphaMab Co Ltd, 2021
  • Hepatitis B - Pipeline by Alphamab Oncology, 2021
  • Hepatitis B - Pipeline by Altimmune Inc, 2021
  • Hepatitis B - Pipeline by Antios Therapeutics Inc, 2021
  • Hepatitis B - Pipeline by Apros Therapeutics Inc, 2021
  • Hepatitis B - Pipeline by Arbutus Biopharma Corp, 2021
  • Hepatitis B - Pipeline by Arcturus Therapeutics Holdings Inc, 2021
  • Hepatitis B - Pipeline by Ascentage Pharma Group International, 2021
  • Hepatitis B - Pipeline by Ascletis Pharma Inc, 2021
  • Hepatitis B - Pipeline by Assembly Biosciences Inc, 2021
  • Hepatitis B - Pipeline by Atea Pharmaceuticals Inc, 2021
  • Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC, 2021
  • Hepatitis B - Pipeline by Auro Vaccines LLC, 2021
  • Hepatitis B - Pipeline by Avalia Immunotherapies Ltd, 2021
  • Hepatitis B - Pipeline by Beijing Advaccine Biotechnology Company Ltd, 2021
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, 2021
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021
  • Hepatitis B - Pipeline by Benitec Biopharma Inc, 2021
  • Hepatitis B - Pipeline by Biological E Ltd, 2021
  • Hepatitis B - Pipeline by Biomics Biopharma Ltd, 2021
  • Hepatitis B - Pipeline by BioNet-Asia Co Ltd, 2021
  • Hepatitis B - Pipeline by Biotron Ltd, 2021
  • Hepatitis B - Pipeline by Bolder Biotechnology Inc, 2021
  • Hepatitis B - Pipeline by Bonac Corp, 2021
  • Hepatitis B - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
  • Hepatitis B - Pipeline by Brickell Biotech Inc, 2021
  • Hepatitis B - Pipeline by BrightGene Bio-Medical Technology Co Ltd, 2021
  • Hepatitis B - Pipeline by Bukwang Pharmaceutical Co Ltd, 2021
  • Hepatitis B - Pipeline by Cadila Healthcare Ltd, 2021
  • Hepatitis B - Dormant Projects, 2021
  • Hepatitis B - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Hepatitis B, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021